

## **ReiThera Partners with Rwanda and Sabin Vaccine Institute in Joint Effort to Combat Marburg Virus Outbreak**

**Rome, Italy November 6<sup>th</sup> 2024** – In collaboration with the Rwandan government and the Sabin Vaccine Institute, ReiThera has continued to support vaccine development and distribution efforts to curb the ongoing Marburg virus outbreak.

As part of this initiative, ReiThera has produced and delivered approximately 1,000 additional investigational vaccine doses for use in a new randomized clinical trial arm within an open-label study currently underway in Rwanda. The additional doses will help address the needs of high-risk populations and assess the vaccine's impact on containing the spread of this infectious disease.

To date, over 2,700 doses have been provided in coordination with the Sabin Vaccine Institute, with over 1,500 frontline healthcare workers already vaccinated. This rapid response, following just nine days after the outbreak declaration on September 27, has been critical in protecting the health and safety of those most vulnerable to the virus.

“ReiThera is committed to working alongside our global partners to address urgent health challenges such as the Marburg virus,” stated ReiThera CEO Stefano Colloca “Our collaboration with Rwandan health officials and the Sabin Vaccine Institute underscores our dedication to delivering advanced biotechnological solutions rapidly and safely. In this instance, deploying investigational vaccines swiftly has been paramount to addressing the pressing needs of affected communities. This couldn’t have been possible without the incredible effort of our QA and P&L team.”

ReiThera continues its effort with health authorities to meet the evolving needs of the outbreak response. Pending regulatory approvals and further requests from the Rwandan government, the company is prepared to scale up production to supply additional doses, ensuring continuity and effectiveness in the nation’s public health response.

### **About ReiThera Srl**

ReiThera Srl is a CDMO company dedicated to technology and process development and GMP manufacturing, providing support for the clinical translation of genetic vaccines and medicinal products for advanced therapies.

The company has extensive expertise in developing scalable processes for viral-vector manufacturing and a consolidated experience in GMP production of Adeno-Associated Vector (AAV), Lentivirus, Adeno Viral vector (AdV), Modified Vaccinia Ankara and Herpes Simplex Vector.

ReiThera's core manufacturing capacity is based in a state-of-the-art facility, which includes stirred-tank bioreactors at scales of 50L, 200L, 1000L, and 2000L, as well as fixed-bed bioreactors for cell growth in adherence. The GMP facility also comprises a filling suite and quality control laboratories.

ReiThera's headquarters, R&D laboratories, and GMP facilities are located in Rome, Italy. For more information, visit [www.reithera.com](http://www.reithera.com)

### **About Sabin Vaccine Institute**

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with three decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world